Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded to “Sell” Rating by Wall Street Zen

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

VNDA has been the subject of a number of other reports. Jefferies Financial Group increased their price target on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. HC Wainwright increased their target price on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, January 5th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vanda Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $13.63.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $6.09 on Friday. The company has a market cap of $359.92 million, a price-to-earnings ratio of -1.63 and a beta of 0.62. The business has a 50 day moving average price of $7.35 and a 200 day moving average price of $5.68. The company has a quick ratio of 3.10, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The business had revenue of $57.22 million during the quarter, compared to the consensus estimate of $59.28 million. Research analysts predict that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of VNDA. AIGH Capital Management LLC bought a new stake in Vanda Pharmaceuticals in the fourth quarter valued at $17,626,000. Millennium Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 220.0% in the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Vanda Pharmaceuticals by 552.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 708,428 shares of the biopharmaceutical company’s stock valued at $6,248,000 after purchasing an additional 599,818 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Vanda Pharmaceuticals by 945.9% in the 2nd quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock worth $2,227,000 after purchasing an additional 426,620 shares during the last quarter. Finally, Empire Financial Management Company LLC increased its position in shares of Vanda Pharmaceuticals by 46.2% during the 4th quarter. Empire Financial Management Company LLC now owns 1,108,245 shares of the biopharmaceutical company’s stock worth $9,775,000 after purchasing an additional 350,154 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

Trending Headlines about Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Zacks Research upgraded Vanda from a “hold” to a “strong‑buy,” which could attract buying interest from momentum and value‑oriented investors. Zacks/TickerReport Upgrade
• Neutral Sentiment: Company released its Q4 and full‑year 2025 financial results and an earnings call recap showing revenue growth but widening losses; this is the baseline data investors will parse for guidance and runway. Vanda Q4 & FY2025 Results (Press Release)
• Negative Sentiment: Q4 results missed expectations: EPS came in as a larger loss and revenue slightly trailed estimates, which prompted the stock reaction and investor uncertainty. Vanda: Q4 Earnings Snapshot
• Negative Sentiment: Vanda lowered FY‑2026 revenue guidance to roughly $230M–$260M versus a consensus near $273M, signaling slower near‑term growth and pressuring valuation and cash‑flow expectations. Guidance in Vanda Q4 Press Release
• Negative Sentiment: Regulatory uncertainty: analysts and commentary highlight meaningful FDA approval risk for Bysanti and imsidolimab, which raises binary event risk and could delay or reduce future revenues. TipRanks: Regulatory Hurdles for Bysanti and Imsidolimab
• Negative Sentiment: Investor legal risk: a Pomerantz LLP investigation into Vanda has been announced, which can increase near‑term sell pressure and legal costs if a suit proceeds. Pomerantz Investor Alert

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.